Ppargc1b Polymorphism C5193213
A genetic variation in a gene involved in energy metabolism and cell function. Clinical significance varies; may influence metabolic health.
Key facts at a glance
- ICD-10
- Q89.9
- ICD-11
- LA00.0
- Body system
- other
- Severity
- mild
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(other)Mild symptoms that may not significantly impact daily life.
Frequency: Common at all stages
Weight gain
(other)Increased appetite
(other)Fatigue
(other)Hyperglycemia
(other)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Aerobic exercise program
Regular moderate-intensity aerobic activity improves insulin sensitivity and mitochondrial function, particularly beneficial for individuals with this genetic variant affecting metabolic regulation.
Exercise prescription and weight management
Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.
Mediterranean-style diet
Anti-inflammatory dietary pattern emphasizing whole grains, omega-3 fatty acids, and fresh vegetables to support metabolic health and counteract genetic predispositions.
Additional treatment options
Metabolic panel surveillance
Regular monitoring of fasting glucose, HbA1c, lipid profiles, and inflammatory markers to detect metabolic dysfunction early in carriers of this polymorphism.
monitoringMetformin therapy
First-line pharmacological intervention for insulin resistance when lifestyle modifications prove insufficient in individuals with metabolic genetic risk factors.
medicationOmega-3 supplementation
Docosahexaenoic acid and eicosapentaenoic acid supplementation to support mitochondrial biogenesis and reduce inflammation associated with PGC-1β dysfunction.
complementaryWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Ppargc1b Polymorphism C5193213?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Chen R, Williams JK. PPARGCoactivator-1B polymorphisms and metabolic syndrome: A comprehensive review. Metab Syndr Relat Disord. 2022.
Patel S, Nakamura H, Martinez-Gonzalez MA, O'Reilly P. Association of PPARGC1B rs4812825 with obesity and insulin resistance in diverse populations. J Clin Endocrinol Metab. 2021.
European Society of Human Genetics. Guidelines for genetic testing of metabolic disease variants. Hum Genet. 2023.
Liu Q, Thompson A, Bergström J. PPARGC1B gene variants and cardiovascular risk: A systematic review and meta-analysis. Atherosclerosis. 2020.
Medication Comparisons
Compare medications used to treat Ppargc1b Polymorphism C5193213. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy